Farxiga and metformin work in fundamentally different ways, and neither is universally “better.” Metformin remains the standard first-line medication for type 2 diabetes because of decades of safety data and a cost as low as $11 per month. Farxiga offers distinct advantages for people with heart failure or chronic kidney disease, but it costs roughly $377 per month without insurance and carries unique risks metformin doesn’t. For most people newly diagnosed with type 2 diabetes, metformin is the starting point. Farxiga tends to shine as an add-on or alternative when specific health concerns are present.
How Each Drug Lowers Blood Sugar
Metformin reduces the amount of glucose your liver releases into your bloodstream and helps your cells respond better to insulin. It’s been used since the 1990s in the U.S. and has one of the longest track records of any diabetes medication.
Farxiga (dapagliflozin) belongs to a newer class called SGLT2 inhibitors. It works in the kidneys, blocking a protein that normally reabsorbs sugar back into your blood. The result is that excess glucose leaves your body through urine. This mechanism is completely independent of insulin, which means Farxiga works even when your body’s insulin production is declining.
Both drugs lower HbA1c (a measure of average blood sugar over two to three months) by similar amounts when used alone. But combining them produces greater reductions in HbA1c, body weight, and blood pressure than either drug on its own, which is why many people end up taking both.
Weight Loss Comparison
Metformin is one of the few diabetes drugs that doesn’t cause weight gain, and it can produce modest weight loss. In a 24-week study of patients with type 2 diabetes and fatty liver disease, those on metformin lost about 3.6 kg (roughly 8 pounds), going from an average of 74.8 kg down to 71.2 kg.
Farxiga produces weight loss through a different route: by flushing calories out as sugar in your urine. When 10 mg of dapagliflozin was added to metformin in a six-month trial, patients lost about 3 kg (6.5 pounds), compared to less than 1 kg in the placebo group. The weight loss with Farxiga tends to be steady over the first several months and then plateaus. Neither drug is a weight loss medication, but both nudge the scale in a favorable direction.
Where Farxiga Pulls Ahead: Heart and Kidney Protection
The strongest case for Farxiga over metformin comes from cardiovascular and kidney data. Metformin has some evidence of heart benefits, but Farxiga has been tested in large, rigorous outcome trials that show measurable reductions in serious events.
In the DECLARE-TIMI 58 trial, patients with type 2 diabetes who had a prior heart attack saw a 16% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) on dapagliflozin compared to placebo. Hospitalizations for heart failure also dropped. These findings led to Farxiga becoming an approved treatment for heart failure, even in people without diabetes.
The kidney data is even more striking. In the DAPA-CKD trial of over 4,300 patients with chronic kidney disease, Farxiga reduced the risk of the combined kidney endpoint (significant kidney function decline, end-stage kidney disease, or death from kidney or cardiovascular causes) by 39% compared to placebo. When looking at kidney outcomes alone, the risk dropped by 44%. The trial was stopped early because the benefits were so clear. The FDA has since approved Farxiga specifically for chronic kidney disease, making it one of the few diabetes drugs with a standalone kidney indication.
If you already have heart failure, reduced kidney function, or protein in your urine, Farxiga offers protection that metformin simply hasn’t demonstrated in trials of this caliber.
Side Effects and Risks
Metformin’s most common side effects are gastrointestinal: nausea, diarrhea, bloating, and stomach cramps. These tend to improve over the first few weeks, especially if you start at a low dose and increase gradually. A rare but serious risk is lactic acidosis, which occurs almost exclusively in people with severe kidney impairment.
Farxiga’s side effects reflect its mechanism. Because it pushes sugar into your urine, it creates a warm, sugar-rich environment that yeast thrives in. Genital yeast infections occur in roughly 5% to 6% of patients on Farxiga, compared to less than 1% on placebo. These infections are typically mild and treatable, but they can be recurrent and frustrating, particularly for women.
Farxiga also carries a small risk of a condition called euglycemic diabetic ketoacidosis, where your blood becomes dangerously acidic even though blood sugar levels look normal or only mildly elevated. This occurs at a rate of about 0.5 per 1,000 patient-years. It’s rare, but it’s tricky because the normal blood sugar reading can delay diagnosis. Risk factors include skipping meals, heavy alcohol use, surgery, and significant illness. If you’re on Farxiga and experience nausea, vomiting, or unusual fatigue, those symptoms warrant prompt attention.
Because Farxiga increases urination, dehydration and low blood pressure can occur, especially in older adults or those on blood pressure medications. Metformin doesn’t have this issue.
Cost and Accessibility
This is where metformin wins decisively. Generic metformin costs between $11 and $23 per month without insurance. Farxiga, which is still under patent, runs about $377 per month at retail price. Insurance and manufacturer coupons can reduce that significantly, but even with coverage, Farxiga copays are often substantially higher than metformin’s. For many people, cost alone determines which drug is practical.
When One Is Preferred Over the Other
Metformin is typically the first medication prescribed after a type 2 diabetes diagnosis. It’s effective, inexpensive, well-studied over decades, and carries a low risk of causing dangerously low blood sugar. For someone whose primary concern is blood sugar control and who doesn’t have heart or kidney complications, metformin is a solid choice.
Farxiga becomes the stronger option when cardiovascular or kidney disease enters the picture. Current guidelines from major diabetes organizations recommend SGLT2 inhibitors like Farxiga for patients with established heart failure, atherosclerotic cardiovascular disease, or chronic kidney disease, sometimes regardless of blood sugar levels. If you’ve had a heart attack, have been diagnosed with heart failure, or have declining kidney function with protein in your urine, Farxiga addresses risks that metformin doesn’t.
Some people can’t tolerate metformin’s GI side effects even after dose adjustments. In those cases, Farxiga can serve as an alternative first-line treatment. Others start on metformin and add Farxiga later when blood sugar targets aren’t met or when heart or kidney protection becomes a priority. The two drugs complement each other well because they work through entirely separate pathways, and combining them doesn’t increase the risk of low blood sugar.